Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Tarlatamab, a DLL3-targeted Bispecific T-cell Engager, in Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma (DeLLight)

NCT06893783 is registered in ClinicalTrials.gov with Inkeun Park as lead sponsor.

NCT NCT06893783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06893783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Tarlatamab, a DLL3-targeted Bispecific T-cell Engager, in Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma (DeLLight)
Lead sponsor
Inkeun Park
Phase
Phase 2
Overall status
Recruiting
Start date
September 2, 2025
Completion date
April 30, 2029
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma of pancreas, neuroendocrine carcinoma of prostate, neuroendocrine carcinomas (nec)